Anticipation in families with MLH1-associated Lynch syndrome

IF 6.1 2区 医学 Q1 ONCOLOGY Cancer Pub Date : 2024-10-22 DOI:10.1002/cncr.35589
Arti S. Pandey PhD, CGC, Christine Drogan CGC, Dezheng Huo PhD, Kristen Postula CGC, Shreshtha M. Garg CGC, Sonia S. Kupfer MD
{"title":"Anticipation in families with MLH1-associated Lynch syndrome","authors":"Arti S. Pandey PhD, CGC,&nbsp;Christine Drogan CGC,&nbsp;Dezheng Huo PhD,&nbsp;Kristen Postula CGC,&nbsp;Shreshtha M. Garg CGC,&nbsp;Sonia S. Kupfer MD","doi":"10.1002/cncr.35589","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Lynch syndrome (LS) is an autosomal-dominant, hereditary cancer predisposition syndrome caused by pathogenic variants (PVs) in one of the mismatch-repair genes <i>MLH1</i>, <i>MSH2/EPCAM</i>, <i>MSH6</i>, or <i>PMS2</i>. Individuals who have <i>MLH1</i> PVs have high lifetime risks of colorectal cancer (CRC) and endometrial cancer (EC). There is controversy regarding whether a younger age at diagnosis (or anticipation) occurs in <i>MLH1</i>-associated LS. The objective of this study was to assess anticipation in families with <i>MLH1-</i>associated LS by using statistical models while controlling for potential confounders.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data from 31 families with <i>MLH1</i> PVs were obtained from an academic registry. Wilcoxon signed-rank tests on parent–child-pairs as well as parametric Weibull and semiparametric Cox proportional hazards and Cox mixed-effects models were used to calculate hazard ratios or to compare mean ages at CRC/EC diagnosis by generation. Models were also corrected for ascertainment bias and birth-cohort effects.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A trend toward younger ages at diagnosis of CRC/EC in successive generations, ranging from 3.2 to 15.7 years, was observed in <i>MLH1</i> PV carrier families. A greater hazard for cancer in younger generations was not precluded by the inclusion of birth cohorts in the model. Individuals who had <i>MLH1</i> variants with no Mlh1 activity were at a 78% greater hazard for CRC/EC than those who retained Mlh1 activity.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The current results demonstrated evidence in support of anticipation in families with <i>MLH1-</i>associated LS across all statistical models. Mutational effects on Mlh1 activity influenced the hazard for CRC/EC. Screening based on the youngest age of cancer diagnosis in MLH1-LS families is recommended.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694239/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35589","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Lynch syndrome (LS) is an autosomal-dominant, hereditary cancer predisposition syndrome caused by pathogenic variants (PVs) in one of the mismatch-repair genes MLH1, MSH2/EPCAM, MSH6, or PMS2. Individuals who have MLH1 PVs have high lifetime risks of colorectal cancer (CRC) and endometrial cancer (EC). There is controversy regarding whether a younger age at diagnosis (or anticipation) occurs in MLH1-associated LS. The objective of this study was to assess anticipation in families with MLH1-associated LS by using statistical models while controlling for potential confounders.

Methods

Data from 31 families with MLH1 PVs were obtained from an academic registry. Wilcoxon signed-rank tests on parent–child-pairs as well as parametric Weibull and semiparametric Cox proportional hazards and Cox mixed-effects models were used to calculate hazard ratios or to compare mean ages at CRC/EC diagnosis by generation. Models were also corrected for ascertainment bias and birth-cohort effects.

Results

A trend toward younger ages at diagnosis of CRC/EC in successive generations, ranging from 3.2 to 15.7 years, was observed in MLH1 PV carrier families. A greater hazard for cancer in younger generations was not precluded by the inclusion of birth cohorts in the model. Individuals who had MLH1 variants with no Mlh1 activity were at a 78% greater hazard for CRC/EC than those who retained Mlh1 activity.

Conclusions

The current results demonstrated evidence in support of anticipation in families with MLH1-associated LS across all statistical models. Mutational effects on Mlh1 activity influenced the hazard for CRC/EC. Screening based on the youngest age of cancer diagnosis in MLH1-LS families is recommended.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与 MLH1 相关的林奇综合征家族的预后。
背景:林奇综合征(LS)是一种常染色体显性遗传性癌症易感综合征,由错配修复基因 MLH1、MSH2/EPCAM、MSH6 或 PMS2 中的一个基因的致病变异(PVs)引起。具有 MLH1 PV 的个体一生中患结直肠癌(CRC)和子宫内膜癌(EC)的风险很高。关于MLH1相关LS的诊断(或预后)年龄是否会更小,目前还存在争议。本研究的目的是在控制潜在混杂因素的同时,利用统计模型评估MLH1相关LS家族的预后情况:方法:从一个学术登记处获得了31个MLH1 PV家族的数据。父母-子女配对的Wilcoxon符号秩检验以及参数Weibull和半参数Cox比例危险模型和Cox混合效应模型用于计算危险比或比较各代CRC/EC诊断的平均年龄。模型还对确诊偏差和出生队列效应进行了校正:结果:在 MLH1 PV 携带者家族中,发现 CRC/EC 诊断年龄有逐代降低的趋势,从 3.2 岁到 15.7 岁不等。在模型中加入出生队列并不排除年轻一代患癌症的风险更大。与保留 Mlh1 活性的人相比,具有 MLH1 变异但没有 Mlh1 活性的人患 CRC/EC 的风险高出 78%:目前的研究结果表明,在所有统计模型中,都有证据支持对MLH1相关LS家族的预测。Mlh1活性的突变效应影响了CRC/EC的发病风险。建议根据MLH1-LS家族癌症诊断的最小年龄进行筛查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
期刊最新文献
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study Relationships between patient-reported and clinician-rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy Estimating cancer incidence attributable to physical inactivity in the United States Job descriptions by oncology patient navigator experience Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1